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Parkinson's disease and the bones
Abstract
Any newly diagnosed patient with PD should be evaluated for the risk of falling and
osteoporosis and routinely be supplemented with vitamin D. In the case of osteoporosis, blood
samples for detecting underlying and treatable conditions should be taken and
bisphosphonates administered to the patient. It is unclear whether drugs typically used for PD
provoke or worsen osteoporosis. Nevertheless, every long-term medication should undergo
safety studies to demonstrate lack of negative interference with bone metabolism. Drug
admission authorities should demand these data when registering new substances or when
renewing old admissions.
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Summary
PRINCIPLES: Bone and joint problems in Parkinson’s dis-
ease (PD) are manifold: decreased mobility, abnormal pos-
ture, as well as the risk of falling may cause both acute and
chronic damage to the musculoskeletal system. In patients
with Parkinson’s disease, postural instability and falls are
frequently observed. The aim of the study was to review
the literature with respect to the bone health and risk of
fractures in these patients.
METHODS: We conducted a review on bone health in pa-
tients with Parkinson’s disease.
RESULTS: There is evidence that patients with PD have
an increased risk of fractures, especially of the hip, due
to the elevated risk of falling. While rigidity, bradykinesia
and postural instability (but not tremor) predict falls, frac-
tures also correlate with bone mineral density, which is
generally lowered in this group of patients as compared to
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BMD Bone mineral density
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COMT Catechol-O-methyltransferase
DXA Dual energy X-ray absorptiometry
DPD-CL Desoxypyridinoline crosslinks
GH Growth hormone
HR Hazard rate
Hcy Homocysteine
IGF-1 Insulin-like growth factor 1
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age- and sex-matched controls. Typically PD patients have
“high turnover osteoporosis” due to several causes.
CONCLUSIONS: Any newly diagnosed patient with PD
should be evaluated for the risk of falling and osteoporosis
and routinely be supplemented with vitamin D. In the case
of osteoporosis, blood samples for detecting underlying
and treatable conditions should be taken and bisphosphon-
ates administered to the patient.
It is unclear whether drugs typically used for PD provoke
or worsen osteoporosis. Nevertheless, every long-term
medication should undergo safety studies to demonstrate
lack of negative interference with bone metabolism. Drug
admission authorities should demand these data when re-
gistering new substances or when renewing old admissions.
Key words: Parkinson’s disease; accidental falls; bone
fractures; bone density; osteoporosis; levodopa;
homocysteine; vitamin D
Background
Almost two centuries have passed since James Parkinson
introduced his “shaking palsy” to the scientific community
[1] and Charcot coined the term “Parkinson’s Disease”
(PD). In the meantime many things have changed. People
are getting older and many patients will suffer from this
disease whose incidence is related to advanced age [2]. Ef-
ficacious drug treatments have only been available since
the 70’s, with amantadine and L-dopa plus
dopadecarboxylase-inhibitors. Other drugs followed later
such as dopamine agonists, monoamino-oxidase (MAO)
B- and catechol-O-methyltransferase (COMT)-inhibitors.
While placement of lesions stereotactically has turned out
to be a “blind alley” and has been largely abandoned, so-
called “deep brain stimulation” electrodes have been suc-
cessfully implanted for 20 years and are now a standard
therapeutic option [3]. Yet we are still awaiting curative
treatment. The present therapeutic armamentarium offers a
better quality of life for patients affected by this chronic-
progressive neurodegenerative disease. However, a better
and possibly longer life also means more long-term health
problems [4], both neurological (e.g., dementia) and non-
neurological (e.g., musculoskeletal). Bone and joint prob-
lems in PD are manifold: decreased mobility, abnormal
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posture, as well as the risk of falling may cause both acute
and chronic damage to the musculoskeletal system [5]. Ad-
ditionally, drug therapy itself might also have an influen-
ce on the musculoskeletal system. Hence we will focus on
the factors affecting bone metabolism and fractures in PD.
Thus, the aim of the study was to review the literature with
respect to the risk of falling and fractures in these patients.
Methods
For this review, we searched Embase and Medline (table 1).
In terms of falls, fractures, mortality and bone mineral
density (BMD), we selected papers comparing PD patients
with normal controls. We also included studies carried out
among PD patients distinguishing “fallers” from “non-
fallers”. For BMD, we selected studies measuring lumbar
spine and femur with dual energy X-ray absorptiometry
(DXA).
We completed our database by asking pharmaceutical com-
panies which manufacture the above-mentioned (table 1,
“search E”) drugs for PD about a) systematic safety studies
for bone integrity and b) incidental data referring to effects
of their antiparkinson drugs on bone metabolism.
Values are reported as given in the original articles, i.e.,
mean ± SD or mean (lower-upper CI 95%) if not stated oth-
erwise. Statistical inference testing is reported as cited from
the original papers.
Results
Figure 1
Metacarpal bone mineral density changes (mean + SEM) in
patients with Parkinson’s disease, treated with menatetrenone,
calcium and vitamin D, compared with calcium and vitamin D alone
or without bone treatment (n = 56, 60 or 54 respectively). ANCOVA:
p <0.001 for both groups treated with calcium and vitamin D vs
untreated, and p = 0.05 for menatetrenone, calcium and vitamin D
vs calcium and vitamin D alone [60, with permission of the editor].
Falls
Falls are frequent in PD. Most studies investigated risk
factors for falling within PD patients. Two studies com-
pared fall risk in PD with controls. Bloem et al. published
a 6-month study [6]: 51% of PD patients fell at least once
compared to 15% in the control group, corresponding to
a risk ratio (RR) of 3.4. Because many PD patients had
more than one fall, there were 3.5 falls per patient com-
pared to 0.2 in the control group. Camicioli et al. also found
an increased risk of falling (RR 1.4) [7]. The risk for re-
peatedly falling was increased by 2.6. During periods ran-
ging from two to twelve months, in patients with PD, the
proportion falling ranged from 25% to 78% (mean value
50%) [8–13]. In their meta-analysis, Deandra et al. found
an odds ratio (OR) of 2.71 (1.08–6.84) for falling in PD
[14]. Fall frequency seems to correlate with PD symptom
severity [6, 9, 11], time since disease onset [13, 15], fe-
male gender or autonomic dysfunction [16], urinary incon-
tinence [13] and dementia [15]. A simple battery of clinical
tests can predict fall risk in PD patients with 78% sens-
itivity and 84% specificity [17]. Finally, besides previous
falls, the most prominent predictors of falls seem to be
gait disturbances and postural instability, known to be more
frequent in advanced stages of the disease [10, 11, 16].
The latter can be detected by clinical tests [18], but also
be objectively measured with electronic walkways such as
the GAITRite system, with movement analysis such as the
Vicon system, with force platforms and with acceleromet-
ers [19] or with computerised dynamic posturography [20].
Gait disturbances and postural instability can be partially
mitigated by physiotherapeutic exercises [8, 21–24]. Even
in the absence of a complete clinical Parkinson syndrome,
single clinical signs associated with PD may increase the
risk of falls [25]. Postural instability may be the only clin-
ical sign of patients with repetitive falls and may improve
after dopaminergic treatment such as amantadine or L-dopa
[26]. This medication will not be generally very effective
although in some patients clinical conditions may dramat-
ically improve. Cholinergic treatment with donezepil was
recently described to prevent falls in non-demented PD pa-
tients [27]. We did not find published information whether
these drugs also prevent fractures. Overall, falls are a typ-
ical sign of late stages of PD, explaining why they are often
associated with dementia or autonomic dysfunction, condi-
tions themselves associated with falls independently of PD
[7]. Preliminary data suggest that pedunculopontine “deep
brain stimulation” may improve axial symptoms and gait
[28]. Current literature on falls in PD has been reviewed by
Grimbergen et al. [29].
Table 1: Search strategy.
A Falls: Parkinson’s disease AND accidental falls (530, 16, 7)
B Fractures: Parkinson’s disease AND bone fracture (338, 5, 4)
C Mortality: Parkinson’s disease AND mortality (1028, 10, 3)
D Bone density and metabolism: Parkinson’s disease AND (osteoporosis OR osteopenia OR bone mineral density OR NTx OR hydroxyproline OR undercarboxylated
osteocalcin OR ICTP OR desoxypyridinoline) (356, 14, 1)
E Iatrogenic effects: (L-dopa OR benserazide OR carbidopa OR bromocriptine OR cabergoline OR pergolide OR pramipexole OR ropinirol OR rotigotine OR lisuride OR
quinagolide OR entacapone OR tolcapone OR amantadine OR selegiline OR rasagiline) AND (osteoporosis OR osteopenia OR bone mineral density OR NTx OR
hydroxyproline OR undercarboxylated osteocalcin OR ICTP OR desoxypyridinoline) (411, 5, 13)
Legend: The first number represents the hits found within Embase or Medline in November 2010, the second the papers included, the third number the papers found by
other strategies like manual searches in citations of other papers. No wildcards were used for searching.
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Fractures
Patients in the late stages of PD seem to fall sideways or
backwards with disproportionate frequency [30], probably
because of slowed postural reflexes. This leads to a typic-
al pattern of fractures with an excess of hip fractures com-
pared to other locations. Studies investigating hip fractures
in PD as compared with controls are summarised in table
2. In the Olmsted County cohort study by Johnell et al.
[30], 138 patients with PD were retrospectively compared
with age- and sex-matched controls. The mean observa-
tional period was 6.8 years in PD and 8.6 years in controls.
During this interval, 20 patients with PD suffered from hip
fractures, compared with one person in the control group
(RR 20.0); fractures of other locations were more evenly
distributed: 68 in PD and 38 in controls (RR 1.8). In a ret-
rospective cohort study done by Genever et al. [31] dur-
ing a mean interval of 5.9 years, 200 patients with PD and
controls were analysed. Eleven hip fractures occurred in
the PD group compared to four in controls (RR 2.8). There
were 27 fractures in other locations in PD and twelve in
controls (RR 2.3). In 2008 Schneider et al. published the
“Study of Osteoporotic Fractures (SOF) Research” in fe-
male patients [32]. During a prospective nine-year follow-
up, 11 hip fractures occurred in 73 PD patients (15%),
while 839 of 7760 con-trols had hip fractures (11%, RR
1.4). There were 11 other fractures (excluding vertebral) in
73 PD (15%) and 1589 in 6349 controls (25%, RR 0.6).
Adjusted for age, RR for hip fractures in PD was 2.6 (95%
CI 1.4–4.6), but when controlling for weight, RR fell to 1.7
(0.8–3.9). Obviously fractures were correlated to poor nu-
tritional status; during the study period, PD patients lost on
average 4.6 ± 7.2 percent of their body weight, as com-
pared to 0.6 ± 6.6% in controls. In a shorter study on males
done by Fink et al., lasting on average 4.1 (PD) to 5.1
(controls) years, 7 of 46 patients with PD (15%) were re-
gistered with fractures, as compared to 424 out of 5891
control subjects (7%) [33]. In this study the hazard ratio
for non-vertebral fractures was 2.4 (95% CI, 1.1–5.0). In an
older study with female patients, the RR was 9.4 (1.2–76.1)
[34]. In a study done by Taylor et al. in women, PD was
the strongest single predictor of fractures [35], but this was
not independent of BMD. In another study by Nguyen et
al., body sway and BMD best explained the fractures that
were observed [36]. In a large Danish case-control study,
RR for any fracture in PD was 2.2 (95% CI 2.0–2.5) [37];
yet, this ratio fell to 1.5 (1.3–1.8) when adjusting for use of
antiparkinson drugs and further to 1.2 (1.0–1.4) when vari-
ous anamnestic factors were included. Large prospective
observational as well as intervention studies on fractures
in PD are lacking. Considering that 90% of non-vertebral
fractures result from falls [38], fall prevention remains the
most effective measure to prevent fractures.
Overall Mortality
We did not find studies, which separately analysed mortal-
ity rates resulting from fractures, yet several studies repor-
ted overall mortality in PD. Diem et al. reviewed mortality
in PD [39]. In a total of 33 cohort studies, during a mean
follow-up of 9.6 years, in 8081 patients, RR for mortality
was 1.8 (these results are reported without the large study
by Guttman, 6 yr, 15304 patients, RR 2.5). The mortality
rates were higher in two pre-dopa studies (2.3) as compared
to the post-dopa era (1.8). Another meta-analysis by Berger
et al. on five studies reported a RR of 2.3 (1.8–3.0) [40]. He
showed also a high rate of institutionalisation in 229 PD pa-
tients compared to 13 051 controls (RR 5.0; 3.3–7.4). Co-
hort studies are very sensitive to inequalities in the control
group, e.g., non-inclusion of terminally ill patients, there-
fore these results could overestimate mortality. A measure
to avoid this possible bias is to calculate standardised mor-
tality rates (SMR) by comparing mortality in PD cohorts
with that of the general population. This has been done
by Herlofson et al. [41], Hely et al. [42] and Hobson et
al. [43]. In 245, 126 or 166 PD patients, followed for 8,
15 or 4 years, SMR was reported to be 1.52 (1.29–1.79),
1.86 (1.48–2.31) or 2.1 (1.7–2.6), respectively. During her
20-year follow-up, Diem et al. [39] followed 238 PD pa-
tients. She found slightly increased overall SMR of 1.3
(1.1–1.6) for men, while women’s SMR was not signific-
antly elevated (1.2; 0.9–1.4). She also described elevated
SMR values 15 and more years after disease onset, so in-
creased mortality may be a phenomenon of longstanding
PD. Her analysis of mortality according to time after dis-
ease onset was later criticised by Rajput et al. [44]. In the
PD group, no deaths could have occurred between disease
onset and inclusion to the study, while in controls this was
the case, so underestimation of mortality in PD was the
consequence. A study by Mylne et al. described an approx-
imate 20% decline in PD mortality over the time period
from 1993–2006 [45]. Several studies reported pneumonia
as a major cause of death in PD [46–50 but this observa-
tion could not be reproduced by Diem et al. [39]. Detec-
tion of causes of death from mortality registries seems dif-
ficult because of changing habits of coding over time and
lack of precision. In the study by Diem et al., 23% of deaths
were ascribed to PD itself, and only 7% to pneumonia [39];
perhaps some of the doctors subsumed aspiration pneumo-
nia in patients with swallowing difficulties to PD, others
to “pneumonia”. In another study, increased mortality of
PD patients in winter was described [51]. Male gender, gait
disorder, lack of tremor and lack of asymmetry were asso-
Table 2: Hip fractures in PD compared with normal controls.
First author [Reference Nr.] Year of publication Number of patients /
controls
Duration, yr Outcome Significance Type of study
Johnell O [30] 1992 138 / 138 6.8 / 8.6 RR 20.0 (4.0 – ∞) <0.001 retrospective cohort
Genever RW [31] 2005 200 / 200 5.9 / 5.9 RR 2.8 = 0.07 retrospective cohort
Schneider JL [32] 2008 73 / 8032 9.0 / 9.0 adj. HR 2.6
(1.4–4.6)
not stated prospective cohort,
women only
Fink HA [33] 2008 46 / 5891 4.1 / 5.1 adj. HR 2.4
(1.1–5.0)
not stated prospective cohort, men
only, hip not separately
analysed
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ciated with poorer survival [39]. Fink et al. found that the
presence of gait disturbances in patients with PD almost
doubled the risk of dying [33].
Bone mineral density (BMD)
We found seven studies measuring BMD in g/cm2 by DXA
in PD and control subjects [52–58], they are summarised
in table 3. Mean BMD (total hip) of the 365 patients (48%
female, mean age 68.4 years) with PD was 0.767 g/cm2,
while in control subjects this value was 0.872, a statistically
(p <0.001) significant and clinically important difference.
In the “Osteoporotic Fractures in Men Study (MrOS)” pub-
lished by Fink et al., within a cohort of community-dwell-
ing men, 46 patients with PD were compared with 5891
participants without PD [33]. Mean total hip BMD was
0.876 g/cm2 in PD vs 0.958 without PD (P <0.001). Hence,
PD patients were 1.8 years older than controls. Two studies
investigated annual loss of BMD in PD patients: Lorefält
et al. found a loss of 3.9% vs 1.2% in controls [54], while
in the study done by Fink et al. on male patients the values
were 1.1% vs 0.4% [33]. In two studies done by Sato et al.,
the groups of PD patients receiving no bone-specific treat-
ment (control groups) had a yearly loss of 4.5% or 4.2%
[59, 60] similar to the study of Lorefält et al. mentioned
above. Ishizaki et al. found a slightly more decreased BMD
on the preferentially affected side of PD patients [61]. In
healthy perimenopausal women, yearly bone loss of ap-
proximately 2.0% was described, slowing down to 1.0 to
1.5% three to four years after menopause; thus, the 4% an-
nual loss in PD patients will be twice that expected in peri-
menopausal women [38].
Bone metabolism
Turnover of bone can be measured by markers of bone
degradation. One of them is desoxypyridinoline crosslinks
(DPD-CL) measured in fasting second morning urine ex-
pressed as a ratio to creatinine concentration. Sato et al.
[60] found higher DPD-CL in PD compared to controls
(9.0 ± 1.9 vs 4.0 ± 1.2 μmol/mol creatinine, p <0.001). The
same author demonstrated that treatment with alendronate
or risedronate restored DPD-CL excretion to normal val-
ues [62, 63]. What are the pathophysiological aspects for
high bone turnover in PD? Patients with PD have markedly
lower levels of 25-OH vitamin D3 compared to controls. In
197 patients with PD, serum level was 59.9 ± 37.4 nmol/L,
while in 158 controls 84.2 ± 28.8 nmol/L was measured (p
<0.001) [54, 60, 64]. Low levels of vitamin D3 were more
frequent in patients with PD compared to patients with
Alzheimer’s disease [64]. As a consequence of low vitam-
in D3, low levels of active 1,25-OH vitamin D3 (calcitriol)
were detected [65]. Furthermore in the same article Sato et
al. mentioned elevated levels of ionised calcium in patients
with PD compared to controls which was explained by the
pronounced immobilisation of these patients. A study re-
cently published by the same author demonstrated a pre-
served BMD, a doubling of serum vitamin D, a reduction
of DPD-CL and fewer hip fractures in PD patients by the
simple intervention of 15 minutes’ exposure to sunlight on
sunny days [66]. Finally he described low levels of vitam-
in K1 in patients with PD, compromising the synthesis of
carboxylated osteocalcin and contributing therefore to os-
teoporosis. Further bone loss was prevented after substitu-
tion with vitamin K2 (menatetrenone) [60] (fig. 1).
Pills and bone
Although musculoskeletal problems are well known in PD,
bone pathology is a neglected issue in PD treatment. Phar-
maceutical companies admitted upon our request that sys-
tematic safety studies for bone integrity during tests with
their antiparkinsonian drugs are lacking. Our literature
search did not reveal any prospective study on bone miner-
al density or bone metabolism during treatment with drugs
typically used for symptomatic treatment of PD. Rico et al.
did not find significant effects on cortical bone mass when
investigating eleven PD patients receiving L-dopa for six
years [67]. Thus, he could not replicate alleged favourable
effects of L-dopa on bone metabolism published only as an
abstract. There is no statement which dopadecarboxylase-
inhibitor (benserazide or carbidopa) was taken together
with L-Dopa. In a Danish study done by Vestergaard et al.,
fracture risk was increased with L-dopa treatment (RR 1.8)
[37]. In a case-control study by Arbouw et al., the current
use of dopaminergic drugs was correlated to hip fractures
(ORajd 1.76; 95%CI 1.39–2.22) [68].
When looking for indirect interactions of the drugs for PD
with bone metabolism such as renal or endocrinological
changes in humans or bone alterations in animals, some
preclinical studies were found. Concerning the kidney, a
study by Inglis et al. documented high concentrations of
epinephrine in the renal cortex following administration of
L-dopa in rats [69]. In studies done by Luippold et al. hy-
perfiltration, diuresis and natriuresis mediated by dopam-
ine3 and in part by dopamine2 receptors were observed [70,
Table 3: Bone mineral density in PD compared with normal controls.
First author / Reference Nr. Year of publication Number of
patients / controls
BMD total hip,
g/cm2 (SD)
Significance Type of study, comments
Kao CH [52] 1994 22 / not stated 0.92 / 1.19 Not stated Case series, historical controls
Taggart H [53] 1995 55 / 55 0.72 (0.19) /
0.80 (0.15)
= 0.02 Controls were patients sent to DXA scan
Lorefält B [54] 2007 26 / 26 0.74 (0.1) /
0.80 (0.1)
<0.05 Randomised controls
Abou-Raya S [55] 2009 82 / 68 0.72 (0.09) /
0.96 (0.05)
= 0.005 Femoral neck density.
Bezza A [56] 2008 52 / 52 0.96 (0.15) /
1.05 (0.16)
= 0.03 Provenance of controls not stated
Kamanly A [57] 2008 24 / 26 0.72 / 0.71 n.s. Only in women significant difference.
Lam K [58] 2010 104 / 208 0.72 / 0.74 n.s. Femoral neck density. Significant in women
only.
Review article Swiss Med Wkly. 2011;141:w13154
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 9
71]. Deletion of the dopamine transporter gene in mice res-
ults in deficiencies of skeletal structure and integrity [72].
Influences of L-dopa on the endocrine system have been
shown: L-dopa is known to increase release of growth hor-
mone (GH) and thus IGF-1 [73]. This effect is even used
as a provocation test for measuring normal pituitary func-
tion [74]. In the study conducted by Rico mentioned above,
GH stimulation was the underlying mechanism discussed
to explain the supposed positive effect of L-dopa on bone.
Finally, lower BMD in post-menopausal women with low
IGF-1 points to an effect of GH in long-term bone mass
regulation [74] and hence to a lever by which dopaminergic
drugs could protect bone mass. Long-term excess of GH, in
contrast, probably does affect the skeleton negatively, due
to unfavourable changes in the micro architecture and mat-
rix composition [75]. Interestingly, GH levels of treatment-
naive patients with PD are lowered [76].
In the presence of dopadecarboxylase-inhibitors, L-dopa
is preferentially metabolised by catechol-O-methyltrans-
ferase (COMT) to S-adenosylmethionine and rapidly con-
verted to S-adenosylhomocysteine and later to homo-
cysteine (Hcy) [77]. Treatment with L-dopa therefore
raises Hcy levels. Elevated Hcy levels seem to be cor-
related with fractures independently from BMD [78–80].
Furthermore, elevated Hcy levels and a high intake of L-
dopa correlate negatively with BMD values in PD patients
[79]. In patients with PD treated with L-dopa, hyperhomo-
cysteinaemia and BMD loss were prevented by substitution
with vitamin B12 and folate [81]. Treatment with Vitamin
B12 and folate also reduced hip fracture rates in patients
with ischemic stroke and hyperhomocysteinaemia [82].
Benserazide, the dopadecarboxylase inhibitor included in
Levopar/Madopar®, was investigated in two studies in
terms of bone changes in rats [83, 84]. Both studies show
dose-dependent marked ephiphyseal growth disturbance
due to lost columnar organization of epiphyseal cartilagin-
eous tissue, followed by ossifications and grotesque com-
pression dislocations in the epiphysis. Morphologically, the
changes have some similarity to rickets and to osteola-
thyrism (a condition linked to defective collagen cross-
linking), although neither pattern fits perfectly. Ultimately,
rats may not be the appropriate animal model to demon-
strate bone safety of drugs aimed at use in humans, because
the epiphyses remain open throughout their life spans. Thus
some of the problems described could only be relevant
for use of benserazide in children with a growing skeleton
[84]. As for carbidopa, the dopadecarboxylase inhibitor in-
cluded in Sinemet®, we did not find any studies reflecting
on bone metabolism.
Discussion
Bone health and bone disease are neglected issues in PD.
We have given here an overview of the current knowledge
and uncovered the blind spots. PD is a chronic disease,
but some non-motor symptoms like constipation, anaemia,
anxiety disorder or REM sleep irregularities are very fre-
quent and may precede the onset of typical PD motor af-
fections by five up to twenty years [85]. Hence, mortality
of PD patients seems not to be relevantly increased, at least
during the first ten years of the disease [39]. So, chronic
endogenous problems like vitamin D deficiency may have
plenty of time to weaken the bones in patients with PD.
Falls are frequent in PD and seem to correlate with typical
cardinal symptoms of PD, like postural instability, bradyk-
inesia or rigidity [10]. Pathologies of both dopaminergic
and non-dopaminergic systems play a role. In particular,
postural instability has been linked to the degeneration of
the non-dopaminergic neurotransmitter system occurring in
late stages of the disease. Cholinergic mesencephalic neur-
on dysfunction is of major importance in understanding
gait and postural disorders in PD and explains why falls
are a serious medical problem mainly in patients in the late
stages of PD [86, 87]. Furthermore, fear of falling seems
to be associated with recurrent falls in patients with PD
[88]. Independently of PD, any patient who repeatedly falls
should be treated using an interdisciplinary diagnostic and
therapeutic approach [89–91].
Two major risk factors are crucial for bone fractures: falls,
and porous bones with compromised mechanical strength.
Characterising bone quality with regard to loss of trabecu-
lar continuity in high turnover osteoporosis requires bone
biopsies and is not feasible for epidemiological purposes.
So studies on bone alterations in PD are usually based on
measuring the quantity of mineralised bone. Most stud-
ies have described lowered BMD in PD. Typically “high
turnover osteoporosis” is found in this group of patients.
It is characterised as lowered BMD in the presence of el-
evated levels of bone resorption markers. Hence, lowered
BMD accounts for a maximally fourfold risk increase for
hip fracture, while other factors like age explain an up to
tenfold risk excess [38]. One of them may be sarcopenia
as found frequently in PD patients [92]. Besides the com-
pelling assessment of classical risk factors, elderly patients
should be evaluated for fracture risk in the following cases:
history of falls, fainting or loss of consciousness; muscle
weakness; dizziness, coordination or balance problems;
difficulty standing or walking; osteoarthritis of the lower
limbs; neuropathy and vision loss [38]. In particular, pa-
tients with swallowing disturbances are prone to losing
weight and developing hypo-nutrition with mineral, protein
and vitamin deficiencies. Lack of exposure to sunlight and
its consecutive vitamin D deficiency will also be frequent
in these patients. In their review published in 2009, In-
vernizzi et al. question whether vitamin D deficiency itself
could trigger neurodegenerative progression of PD [93].
New data, recently published by Knekt et al. seem to sup-
port his hypothesis [94]. The pathophysiologic role of GH,
IGF-1, PTH, leptine, osteoprotegerine, PPAR-γ and
RANKL in this special type of osteoporosis in PD has still
to be elucidated.
One cornerstone for fracture risk evaluation is DXA meas-
urement of BMD. In Switzerland, health insurance com-
panies will only reimburse DXA in the following cases: 1)
manifest osteoporosis or pathological fracture in the past,
2) hypogonadism, 3) long-term treatment with corticoster-
oids, 4) primary hyperparathyreoidism, 5) osteogenesis im-
perfecta, 6) malabsorptive gastrointestinal diseases, or 7)
therapy control after two years. This list should be exten-
ded to A) elevated risk of falls, B) immobility by other dis-
ease, or C) long-term medication known to reduce BMD.
The actual costs of approximately CHF, US$ or € 180.–
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seem moderate when compared with the potential health
benefit for patients.
Until now, bone loss was mostly explained by the immob-
ility of patients with PD. For example, Sato et al. described
a similar pattern of bone mineral loss in patients after
stroke [95]. Better mobility of PD patients treated with
antiparkinsonian agents should therefore increase muscu-
lar strength or increase outdoor activity allowing vitamin
D production. Thus, when applying Occam’s razor to the
question whether low BMD in PD needs other explanations
than immobility and hypo-nutrition, the oracle’s answer
would certainly have been “there is no need!” But there are
nowadays some reasons to assume that drugs typically used
for PD may cause or worsen bone problems in these pa-
tients. Osteoporosis can be provoked by benserazide in a
rat model. There is evidence of renal and endocrinological
effects of dopaminergic drugs in animals as well as in hu-
mans. L-Dopa increases Hcy and GH levels. Hyperhomo-
cysteinemia is associated with osteoporosis and elevated
fracture risk. Even direct [96] and indirect by GH [75] or
Hcy [97] effects of L-dopa inhibiting collagen biosynthesis
have been described. If one corrects hypovitaminosis D and
low calcium intake in patients with PD, bone loss is mitig-
ated (fig. 1), and if one adds vitamin K2 (menatetrenone),
further bone loss will be prevented – but “high turnover os-
teoporosis” in terms of DPD-CL excretion will still persist
[60]. Bone turnover is only restored to normal values in PD
when patients are treated with bisphosphonates [62, 63].
Hyperhomocysteinaemia is correlated with osteoporosis
[79, 80], dementia [98] and cardiovascular problems [99].
Supplementation with folate and vitamin B12 seems to fa-
vourably influence osteoporosis in PD patients [81], effects
on PD dementia remain to be evaluated, whereas these sup-
plements seem to not alter cardiovascular prognosis [100].
Starting dopaminergic treatment with dopamine agonists
instead of L-dopa [101] and adding a COMT-inhibitor to
L-dopa (Stalevo®) instead of increasing the dose to high or
very high levels [101, 102] and liberal application of vit-
amin B12 and folic acid could be favourable for limiting
hyperhomocysteinaemia in PD patients.
Osteoporosis is a silent disease and bones do not complain
until they break. If a condition is linked to bone problems,
the individual consequences will only come to light much
later. Not one of the eleven pharmaceutical companies
selling drugs for symptomatic treatment of PD in Switzer-
land stated that they had undertaken systematic studies for
bone integrity in PD. We know about several groups of
drugs causing or worsening osteoporosis in men. Some
less-known examples are antiepileptic drugs [103], antico-
agulants [104], antidiabetics [105], antidepressants [106]
and proton pump inhibitors [107], all of which are widely
used. Why is systematic research for bone health in this
vulnerable group of PD patients still lacking? Firstly, stud-
ies investigating symptomatic treatments of PD are de-
signed by neurologists, not by rheumatologists or general
practitioners. Therefore trials will naturally be focused on
neurological changes and not on long-term side effects af-
fecting bone quality and bone strength. Secondly, there is
no compelling stimulus for pharmaceutical companies to
care about bone safety. Drugs typically used for PD will
also be administered to patients with “restless legs syn-
drome” – but even for this indication, bone safety studies
are absent. The complete lack of studies on long-term ef-
fects of PD drugs on bone metabolism should be corrected
by regulatory authorities.
Bone integrity should not be the only concern in long-
term treatment: we have learnt a lot from the Vioxx® story
[108] in terms of drug surveillance. Other topics to monitor
could be of great interest such as heart attacks, loss of
kidney function, liver cirrhosis, diabetes or macular de-
generation. An international database for long-term drug
safety could be helpful, as well as meticulous control for
health problems associated with medical treatment in large
cohort studies (e.g., the Australian “45 and Up Study”;
www.45andUp.org.au). To put it frankly: epidemiological
studies and observational trials can provide hints to pos-
sible health problems, but nothing can replace prospective
safety studies.
Limitations
Our article represents an overview including the available
literature addressing the problem “bone disease” in patients
with PD. Although we performed a broad and unrestricted
literature search, we did not find many high quality studies;
if we are contending a lack of evidence, we cannot be
sure of not having overlooked studies undetected by our
search strategy. Some of the studies cited in this review are
more than 20 years old. Since then antiparkinsonian treat-
ments as well as life style and health services have changed
– maybe our notions on fall risk and fractures cannot be
translated into current health care of PD patients.
As mentioned above, prospective studies with respect to
bone metabolism during a defined drug treatment for PD
are completely lacking. There are observational studies on
fall risk, fractures and BMD in patients with PD, but these
studies are mostly retrospective and do not define exactly
which drugs were given to the patients. Some small in-
tervention studies address bone integrity but not elevated
fracture risk in PD. Interventions were done with vitamin
D and calcium, menenatrenone (vitamin K2), vitamin B12,
folate, bisphosphonates and sunlight exposure. Since the
2009 review of Invernizzi et al. on the same topic as ours,
the data of Jung-Min Koh’s Korean group have now been
published, backing theories about iatrogenic influences on
osteoporosis in PD patients [79, 81]. The available data
cannot however definitively answer the question whether
symptomatic treatment of PD will do harm to the skeleton
– there is some evidence that this is a point of concern,
but our opinion is that yes: L-dopa, particularly in higher
doses, indeed leads to “high turnover osteoporosis” in PD
patients. We still need more prospective studies of good
quality bringing light into the complexity of PD, its medic-
ation and the consequences for the musculoskeletal system.
Conclusions
The skeleton of patients with PD is obviously in danger of
frequent falls and bone mineral loss. Any newly diagnosed
patient with PD should be clinically evaluated for fracture
risk and usually undergo bone densitometry to detect osteo-
porosis. Hypo-nutrition should be ruled out. If it is present,
the patient should be referred to a nutritional specialist for
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counseling. In all patients, routine vitamin D substitution
should be started. In cases of osteoporosis, blood samples
should be taken to rule out other secondary causes (incl.
vitamin K deficiency), and treatment with bisphosphonates
started. In cases of pronounced bradykinesia, rigidity and
especially postural instability, physiotherapy should be ini-
tiated and hip protector devices should be discussed with
the patient, preferentially if the patient falls frequently. Ir-
respective of PD, each patient who newly starts falling
should undergo an interdisciplinary diagnostic and thera-
peutic approach to characterise his risk of osteoporosis and
falls.
Every medication applied for long-term treatment of a
chronic disease should undergo safety studies for bone pre-
servation. Drug admission authorities should demand these
data when registering new substances or when renewing
old admissions.
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